Annovis Bio, Inc.(ANVS)Earnings, Financials & Key RatiosAnnovis Bio, Inc. (ANVS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external capital is unsustainable given the rapid depletion of assets to $16.2 million and the lack of commercial revenue to offset $18.0 million in quarterly operating losses.
Annovis Bio, Inc. (ANVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Annovis Bio, Inc. (ANVS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.63vs $0.40-59.5% | — |
| Q2 2026 | Mar 16, 2026 | $0.39vs $0.31-26.5% | — |
| Q4 2025 | Nov 12, 2025 | $0.37vs $0.36-2.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.32vs $0.36+11.1% | — |
Recent stock market news and headlines for Annovis Bio, Inc. (ANVS)
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.
Key metrics vs top competitors for Annovis Bio, Inc. (ANVS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.92 | $37.77M | -1.37 | — | — | -220.61% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $2.71 | $251.14M | -5.02 | — | — | -38.76% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — |
Annovis Bio, Inc. (ANVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Annovis Bio, Inc. (ANVS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 20, 2026·SEC
May 15, 2026·SEC
Apr 10, 2026·SEC
Get notified when ANVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Annovis Bio, Inc. (ANVS) stock FAQ — growth, dividends, profitability & financials explained
Annovis Bio, Inc. (ANVS) reported a net loss of $40.9M for fiscal year 2025.
Annovis Bio, Inc. (ANVS) has a return on equity (ROE) of -220.6%. Negative ROE indicates the company is unprofitable.
Annovis Bio, Inc. (ANVS) had negative free cash flow of $9.03B in fiscal year 2025, likely due to heavy capital investments.
